Jump to content

DPAGT1

From Wikipedia, the free encyclopedia
DPAGT1
Identifiers
AliasesDPAGT1, ALG7, CDG-Ij, CDG1J, CMSTA2, D11S366, DGPT, DPAGT, DPAGT2, G1PT, GPT, UAGT, UGAT, CMS13, dolichyl-phosphate N-acetylglucosaminephosphotransferase 1
External IDsOMIM: 191350; MGI: 1196396; HomoloGene: 1058; GeneCards: DPAGT1; OMA:DPAGT1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1798

13478

Ensembl

ENSG00000172269

ENSMUSG00000032123

UniProt

Q9H3H5

P42867

RefSeq (mRNA)

NM_001382
NM_203316

NM_007875
NM_001364464

RefSeq (protein)

NP_001373

NP_031901
NP_001351393

Location (UCSC)Chr 11: 119.1 – 119.11 MbChr 9: 44.24 – 44.25 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

UDP-N-acetylglucosamine—dolichyl-phosphate N-acetylglucosaminephosphotransferase is an enzyme that in humans is encoded by the DPAGT1 gene.[5][6]

Mutations in DPAGT1 cause myasthenia.[7]

The protein encoded by this gene is an enzyme that catalyzes the first step in the dolichol-linked oligosaccharide pathway (also see Genetic pathway) for glycoprotein biosynthesis. This enzyme belongs to the glycosyltransferase family 4. This protein is an integral membrane protein of the endoplasmic reticulum. The congenital disorder of glycosylation type Ij is caused by mutation in the gene encoding this enzyme. Alternatively spliced transcript variants encoding different isoforms have been identified.[6]

Chemistry

[edit]

DPAGT1 catalyzes the transformation of dolichyl-phosphate N-acetylglucosamine from Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc) and dolichyl-phosphata, which is the first step in N-glycan biosynthesis in mammalian cells.

Uridine diphosphate N-acetylglucosamine + dolichyl-phosphata ↔ dolichyl-phosphate N-acetylglucosamine + UMP

The generated dolichyl-phosphate N-acetylglucosamine is modified via sequential glycosyltransferases, forming Glc3Man9GlcNAc2-P-P-dolichyl which is used for glycosylation of asparagine (Asn or N) residue of polypeptides.

DPAGT1 Catalysis
Synthesis of Dolichyl-P-P-GlcNAc from UPD-GlcNAc and Dolichyl-P via DPAGT1 in N-Glycan Biosynthesis

Structure

[edit]

Despite the challenge of obtaining eukaryotic membrane protein structure, co-crystal structures of DPAGT1 with tunicamycin or UDP-GlcNAc have been reported in 2018. [8] [9] DPAGT1 consists of 10 transmembrane segments (TM1 to 10). Three loops on the endoplasmic reticulum (ER) side and five loops on the cytoplasmic side (Loops A-E) connect the transmembrane segments, where TM4, TM5, TM7, TM8, TM9, Loop A, Loop E form the UDP-GlcNAc binding domain. Dolichyl-phosphate (Dol-P) is predicted to bind the “hydrophobic tunnel” created by TM4, TM5 and TM9 within the lipid bilayer. The uridine moiety of tunicamycin occupies the identical binding sites of UDP-GlcNAc. The lipid tail moiety of tunicamycin occupies the hydrophobic tunnel. Significant conformational changes are observed in the C-terminal end of TM-9, Loop A, and Loop E in DPAGT1-ligand bound structures.

Topology of DPAGT1

Biochemistry

[edit]

Changes and diversification of the expression profile of cell surface glycans based on the underlying glycobiology have received significant attention from the scientific community. N-Linked and O-linked glycans are the most abundant forms of protein glycosylation and occur on proteins destined for the secretory pathway. Recent studies of cancer immunotherapy are based on the immunogenicity of truncated O-glycan chains (e.g., Tn, sTn, T, and sLea/x). Despite the prevalence of N-linked glycan changes in the development of tumor cells, therapeutic antibodies against N-linked glycans have not been developed. This is likely attributable to the lack of specificity of N-linked glycans between normal and malignant cells. Abnormal branching of N-linked glycans has been observed in certain cancer cells. Altered glycosylation of N-linked glycans in cancers is typically associated with upregulation of ß1,6-N-acetylglucosaminyltransferase-3/5 (GnT3/5), enhancing ß1,6-branching.

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000172269 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000032123 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Smith MW, Clark SP, Hutchinson JS, Wei YH, Churukian AC, Daniels LB, et al. (September 1993). "A sequence-tagged site map of human chromosome 11". Genomics. 17 (3): 699–725. doi:10.1006/geno.1993.1392. PMID 8244387.
  6. ^ a b "Entrez Gene: DPAGT1 dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (GlcNAc-1-P transferase)".
  7. ^ Selcen D, Shen XM, Brengman J, Li Y, Stans AA, Wieben E, Engel AG (May 2014). "DPAGT1 myasthenia and myopathy: genetic, phenotypic, and expression studies". Neurology. 82 (20): 1822–1830. doi:10.1212/WNL.0000000000000435. PMC 4035711. PMID 24759841.
  8. ^ Yoo J, Mashalidis EH, Kuk AC, Yamamoto K, Kaeser B, Ichikawa S, Lee SY (March 2018). "GlcNAc-1-P-transferase-tunicamycin complex structure reveals basis for inhibition of N-glycosylation". Nature Structural & Molecular Biology. 25 (3): 217–224. doi:10.1038/s41594-018-0031-y. PMC 5840018. PMID 29459785.
  9. ^ Dong YY, Wang H, Pike AC, Cochrane SA, Hamedzadeh S, Wyszyński FJ, et al. (November 2018). "Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design". Cell. 175 (4): 1045–1058.e16. doi:10.1016/j.cell.2018.10.037. PMC 6218659. PMID 30388443.

Further reading

[edit]
[edit]


Stub icon

This article on a gene on human chromosome 11 is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=DPAGT1&oldid=1187771545"